{"drugs":["Ketoprofen","Orudis","Orudis KT","Oruvail"],"mono":[{"id":"319050-s-0","title":"Generic Names","mono":"Ketoprofen"},{"id":"319050-s-1","title":"Dosing and Indications","sub":[{"id":"319050-s-1-4","title":"Adult Dosing","mono":"<ul><li>Use lowest effective dose for shortest possible duration<\/li><li><b>Osteoarthritis:<\/b> (Immediate-release): Initial, 75 mg ORALLY 3 times a day OR 50 mg 4 times a day; MAX 300 mg\/day<\/li><li><b>Osteoarthritis:<\/b> (Extended-release): Initial, 200 mg ORALLY once a day; MAX 200 mg\/day<\/li><li><b>Pain (Mild to Moderate):<\/b> 25 to 50 mg ORALLY every 6 to 8 hours as needed, MAX 300 mg\/day<\/li><li><b>Primary dysmenorrhea:<\/b> 25 to 50 mg ORALLY every 6 to 8 hours as needed; MAX 300 mg\/day<\/li><li><b>Rheumatoid arthritis:<\/b> (Immediate-release): Initial, 75 mg ORALLY 3 times a day OR 50 mg 4 times a day; MAX 300 mg\/day<\/li><li><b>Rheumatoid arthritis:<\/b> (Extended-release): Initial, 200 mg ORALLY once a day; MAX 200 mg\/day<\/li><\/ul>"},{"id":"319050-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>Safety and efficacy not established in pediatric patients<\/li><li><b>Osteoarthritis:<\/b> 25 to 50 mg twice a day has been effective in relieving pain and morning stiffness in children with juvenile chronic arthritis (study dose).<\/li><li><b>Rheumatoid arthritis:<\/b> 25 to 50 mg ORALLY twice daily has been used (study dose)<\/li><\/ul>"},{"id":"319050-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>Renal impairment, mild:<\/b>, MAX 150 mg\/day<\/li><li><b>Renal impairment, CrCl less than 25 mL\/min or ESRD:<\/b> MAX 100 mg\/day<\/li><li><b>Hepatic impairment and serum albumin less than 3.5 g\/dL:<\/b> MAX 100 mg\/day<\/li><li><b>Geriatric, 75 years or older:<\/b> Reduce initial dose<\/li><li><b>Hypoalbuminemia and renal impairment:<\/b> Start on lower doses<\/li><\/ul>"},{"id":"319050-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Osteoarthritis<\/li><li>Pain (Mild to Moderate)<\/li><li>Primary dysmenorrhea<\/li><li>Rheumatoid arthritis<\/li><\/ul>"}]},{"id":"319050-s-2","title":"Black Box Warning","mono":"<b>Oral (Tablet; Capsule; Capsule, Extended Release)<\/b><br\/>NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may be increased in patients with cardiovascular disease or risk factors for cardiovascular disease. Ketoprofen is contraindicated for the treatment of perioperative pain in the setting of CABG surgery. NSAIDs can also cause an increased risk of serious gastrointestinal adverse events especially in the elderly, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.<br\/>"},{"id":"319050-s-3","title":"Contraindications\/Warnings","sub":[{"id":"319050-s-3-9","title":"Contraindications","mono":"<ul><li>asthma, urticaria, or allergic-type reaction following aspirin or other NSAID administration; severe anaphylactic reactions, including rare fatalities, have been reported<\/li><li>CABG surgery, treatment of perioperative pain<\/li><li>hypersensitivity to ketoprofen<\/li><\/ul>"},{"id":"319050-s-3-10","title":"Precautions","mono":"<ul><li>cardiovascular thrombotic events; myocardial infarction, stroke, and fatalities have been reported; risk may increase with duration of use<\/li><li>cardiovascular disease, known or risk factors for; increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke<\/li><li>elderly; increased risk of serious gastrointestinal adverse events (bleeding, ulceration, perforation of stomach or intestines) that can occur at any time and without warning; increased risk of renal toxicity or injury<\/li><li>gastrointestinal adverse events; ulceration, bleeding, or perforation of stomach or intestines, potentially fatal may occur without warning; increased risk with concurrent use of aspirin, corticosteroids and anticoagulants, smoking, alcohol use, or poor general health status; monitoring recommended<\/li><li>anaphylactoid reactions have occurred<\/li><li>aspirin triad (bronchospasm in asthmatic patients with rhinitis, with or without nasal polyps following aspirin or NSAID administration); risk of severe, potentially fatal bronchospasm; use not recommended<\/li><li>asthma, preexisting; risk of severe and potentially fatal bronchospasm<\/li><li>coagulation disorders or concomitant use of anticoagulants; may be adversely effected by inhibition of platelet aggregation; monitoring recommended<\/li><li>concomitant use with probenecid not recommended<\/li><li>extended duration of therapy; increased risk of potentially fatal gastrointestinal bleeding, ulceration, or perforation that may occur without warning; increased risk of renal papillary necrosis and other renal injury<\/li><li>fluid retention and edema have been reported<\/li><li>gastrointestinal bleeding, history; increased risk of ulceration, bleeding, or perforation of stomach or intestines, potentially fatal<\/li><li>heart failure; edema and fluid retention have been reported; increased risk of renal toxicity or injury<\/li><li>hepatic dysfunction; increased risk of renal toxicity and liver injury; dosage adjustment may be needed; monitoring recommended<\/li><li>hepatic reactions, including notable elevations in hepatic enzyme levels, jaundice and fatal fulminant hepatitis, liver necrosis, and hepatic failure, have been reported; discontinue use with signs and symptoms, or systemic evidence of hepatic reactions<\/li><li>hypertension; new onset or exacerbation may occur; monitoring recommended<\/li><li>peptic ulcer disease, active or history; increased risk of bleeding, or perforation of stomach or intestines, potentially fatal; monitoring recommended<\/li><li>platelet aggregation, inhibition may result in prolonged bleeding time<\/li><li>renal disease, advanced; use is not recommended<\/li><li>renal impairment; increased risk of renal toxicity or injury; dose adjustment may be needed; monitoring recommended<\/li><li>renal papillary necrosis and other renal injury may occur; increased risk with longer duration of therapy, and concurrent use of ACE inhibitors and diuretics<\/li><li>skin reactions; potentially fatal adverse events including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis may occur; discontinue use with first appearance of rash or other sign<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"319050-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>C (AUS)<\/li><\/ul>"},{"id":"319050-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},{"id":"319050-s-4","title":"Drug Interactions","sub":[{"id":"319050-s-4-13","title":"Contraindicated","mono":"<ul>Ketorolac (theoretical)<\/ul>"},{"id":"319050-s-4-14","title":"Major","mono":"<ul><li>Abciximab (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apixaban (theoretical)<\/li><li>Ardeparin (probable)<\/li><li>Argatroban (theoretical)<\/li><li>Aspirin (theoretical)<\/li><li>Beta Glucan (theoretical)<\/li><li>Bivalirudin (theoretical)<\/li><li>Certoparin (probable)<\/li><li>Cilostazol (theoretical)<\/li><li>Citalopram (probable)<\/li><li>Clopidogrel (probable)<\/li><li>Clovoxamine (probable)<\/li><li>Cyclosporine (established)<\/li><li>Dabigatran Etexilate (theoretical)<\/li><li>Dalteparin (probable)<\/li><li>Danaparoid (probable)<\/li><li>Desirudin (theoretical)<\/li><li>Dipyridamole (theoretical)<\/li><li>Duloxetine (probable)<\/li><li>Edoxaban (established)<\/li><li>Enoxaparin (probable)<\/li><li>Eptifibatide (theoretical)<\/li><li>Erlotinib (theoretical)<\/li><li>Escitalopram (probable)<\/li><li>Femoxetine (probable)<\/li><li>Feverfew (theoretical)<\/li><li>Flesinoxan (probable)<\/li><li>Fluoxetine (probable)<\/li><li>Fondaparinux (theoretical)<\/li><li>Ginkgo (probable)<\/li><li>Gossypol (theoretical)<\/li><li>Heparin (theoretical)<\/li><li>Lepirudin (theoretical)<\/li><li>Levomilnacipran (theoretical)<\/li><li>Meadowsweet (theoretical)<\/li><li>Methotrexate (probable)<\/li><li>Milnacipran (probable)<\/li><li>Nadroparin (probable)<\/li><li>Nefazodone (probable)<\/li><li>Parnaparin (probable)<\/li><li>Paroxetine (probable)<\/li><li>Pemetrexed (theoretical)<\/li><li>Pentosan Polysulfate Sodium (theoretical)<\/li><li>Pentoxifylline (theoretical)<\/li><li>Pralatrexate (theoretical)<\/li><li>Prasugrel (theoretical)<\/li><li>Protein C (theoretical)<\/li><li>Reviparin (probable)<\/li><li>Rivaroxaban (theoretical)<\/li><li>Sibutramine (theoretical)<\/li><li>Tacrolimus (probable)<\/li><li>Teriflunomide (probable)<\/li><li>Ticlopidine (theoretical)<\/li><li>Tinzaparin (probable)<\/li><li>Tirofiban (theoretical)<\/li><li>Venlafaxine (probable)<\/li><li>Vilazodone (theoretical)<\/li><li>Vortioxetine (theoretical)<\/li><li>Warfarin (probable)<\/li><li>Zimeldine (probable)<\/li><\/ul>"},{"id":"319050-s-4-15","title":"Moderate","mono":"<ul><li>Acebutolol (probable)<\/li><li>Alacepril (established)<\/li><li>Alprenolol (probable)<\/li><li>Amiloride (probable)<\/li><li>Amlodipine (probable)<\/li><li>Arotinolol (probable)<\/li><li>Atenolol (probable)<\/li><li>Azilsartan (probable)<\/li><li>Azilsartan Medoxomil (probable)<\/li><li>Azosemide (probable)<\/li><li>Befunolol (probable)<\/li><li>Bemetizide (probable)<\/li><li>Benazepril (established)<\/li><li>Bendroflumethiazide (probable)<\/li><li>Benzthiazide (probable)<\/li><li>Bepridil (probable)<\/li><li>Betaxolol (probable)<\/li><li>Bevantolol (probable)<\/li><li>Bisoprolol (probable)<\/li><li>Bopindolol (probable)<\/li><li>Bucindolol (probable)<\/li><li>Bumetanide (probable)<\/li><li>Bupranolol (probable)<\/li><li>Buthiazide (probable)<\/li><li>Candesartan Cilexetil (probable)<\/li><li>Canrenoate (probable)<\/li><li>Captopril (established)<\/li><li>Carteolol (probable)<\/li><li>Carvedilol (probable)<\/li><li>Celiprolol (probable)<\/li><li>Chlorothiazide (probable)<\/li><li>Chlorpropamide (probable)<\/li><li>Chlorthalidone (probable)<\/li><li>Cilazapril (established)<\/li><li>Clopamide (probable)<\/li><li>Cyclopenthiazide (probable)<\/li><li>Delapril (established)<\/li><li>Desvenlafaxine (probable)<\/li><li>Dilevalol (probable)<\/li><li>Diltiazem (probable)<\/li><li>Enalapril (established)<\/li><li>Enalaprilat (established)<\/li><li>Eprosartan (probable)<\/li><li>Esmolol (probable)<\/li><li>Ethacrynic Acid (probable)<\/li><li>Felodipine (probable)<\/li><li>Flunarizine (probable)<\/li><li>Fosinopril (established)<\/li><li>Furosemide (probable)<\/li><li>Gallopamil (probable)<\/li><li>Glimepiride (probable)<\/li><li>Glipizide (probable)<\/li><li>Glyburide (probable)<\/li><li>Hydrochlorothiazide (probable)<\/li><li>Hydroflumethiazide (probable)<\/li><li>Imidapril (established)<\/li><li>Indapamide (probable)<\/li><li>Irbesartan (probable)<\/li><li>Isradipine (probable)<\/li><li>Labetalol (probable)<\/li><li>Lacidipine (probable)<\/li><li>Landiolol (probable)<\/li><li>Levobunolol (probable)<\/li><li>Lidoflazine (probable)<\/li><li>Lisinopril (established)<\/li><li>Lithium (probable)<\/li><li>Losartan (probable)<\/li><li>Manidipine (probable)<\/li><li>Mepindolol (probable)<\/li><li>Methyclothiazide (probable)<\/li><li>Metipranolol (probable)<\/li><li>Metolazone (probable)<\/li><li>Metoprolol (probable)<\/li><li>Moexipril (established)<\/li><li>Nadolol (probable)<\/li><li>Nateglinide (probable)<\/li><li>Nebivolol (probable)<\/li><li>Nicardipine (probable)<\/li><li>Nifedipine (probable)<\/li><li>Nilvadipine (probable)<\/li><li>Nimodipine (probable)<\/li><li>Nipradilol (probable)<\/li><li>Nisoldipine (probable)<\/li><li>Nitrendipine (probable)<\/li><li>Olmesartan Medoxomil (probable)<\/li><li>Oxprenolol (probable)<\/li><li>Penbutolol (probable)<\/li><li>Pentopril (established)<\/li><li>Perindopril (established)<\/li><li>Pindolol (probable)<\/li><li>Piretanide (probable)<\/li><li>Polythiazide (probable)<\/li><li>Pranidipine (probable)<\/li><li>Propranolol (probable)<\/li><li>Quinapril (established)<\/li><li>Ramipril (established)<\/li><li>Repaglinide (probable)<\/li><li>Sotalol (probable)<\/li><li>Spirapril (established)<\/li><li>Spironolactone (probable)<\/li><li>Talinolol (probable)<\/li><li>Tasosartan (probable)<\/li><li>Telmisartan (probable)<\/li><li>Temocapril (established)<\/li><li>Tertatolol (probable)<\/li><li>Timolol (probable)<\/li><li>Tolazamide (probable)<\/li><li>Tolbutamide (probable)<\/li><li>Torsemide (probable)<\/li><li>Trandolapril (established)<\/li><li>Triamterene (probable)<\/li><li>Trichlormethiazide (probable)<\/li><li>Valsartan (probable)<\/li><li>Verapamil (probable)<\/li><li>Xipamide (probable)<\/li><li>Zofenopril (established)<\/li><\/ul>"}]},{"id":"319050-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Edema (2%)<\/li><li><b>Dermatologic:<\/b>Rash (up to 3%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (3% to 9%), Constipation (3% to 9%), Diarrhea (3% to 9%), Flatulence (3% to 9%), Indigestion (11%), Nausea (3% to 9%)<\/li><li><b>Hepatic:<\/b>Increased liver function test (up to 15%)<\/li><li><b>Neurologic:<\/b>Central nervous system depression (3% to 9%), Central nervous system stimulation (3% to 9%), Dizziness (greater than 1%), Headache (3% to 9%)<\/li><li><b>Ophthalmic:<\/b>Abnormal vision (1% to 3%)<\/li><li><b>Otic:<\/b>Tinnitus (1% to 3%)<\/li><li><b>Renal:<\/b>Renal impairment (3% to 9%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Congestive heart failure (less than 1%), Myocardial infarction (less than 1%), Thrombotic tendency observations<\/li><li><b>Dermatologic:<\/b>Erythroderma (less than 1%), Stevens-Johnson syndrome (less than 1%), Toxic epidermal necrolysis (less than 1%)<\/li><li><b>Gastrointestinal:<\/b>Gastrointestinal hemorrhage, Gastrointestinal perforation (less than 1%), Hematemesis (less than 1%), Peptic ulcer disease<\/li><li><b>Hematologic:<\/b>Agranulocytosis (less than 1%), Hemolysis (less than 1%), Thrombocytopenia (less than 1%)<\/li><li><b>Hepatic:<\/b>Hepatic necrosis, Hepatitis (less than 1%), Jaundice (less than 1%), Liver failure (less than 0.1%)<\/li><li><b>Immunologic:<\/b>Anaphylactoid reaction (less than 1%)<\/li><li><b>Neurologic:<\/b>Cerebrovascular accident<\/li><li><b>Ophthalmic:<\/b>Retinal hemorrhage (less than 1%)<\/li><li><b>Renal:<\/b>Interstitial nephritis (less than 1%), Nephrotoxicity, Papillary necrosis, Renal failure (less than 1%)<\/li><li><b>Respiratory:<\/b>Bronchospasm (less than 1%), Edema of larynx (less than 1%), Hemoptysis (less than 1%)<\/li><\/ul>"},{"id":"319050-s-6","title":"Drug Name Info","sub":{"0":{"id":"319050-s-6-17","title":"US Trade Names","mono":"<ul><li>Orudis<\/li><li>Orudis KT<\/li><li>Oruvail<\/li><\/ul>"},"2":{"id":"319050-s-6-19","title":"Class","mono":"<ul><li>Analgesic<\/li><li>NSAID<\/li><li>Propionic Acid (class)<\/li><\/ul>"},"3":{"id":"319050-s-6-20","title":"Regulatory Status","mono":"RX\/OTC<br\/>"},"4":{"id":"319050-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},{"id":"319050-s-7","title":"Mechanism Of Action","mono":"Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) with both analgesic and antipyretic activities. The exact mechanism of action is unknown but its anti-inflammatory effect is thought to be related to its ability to inhibit prostaglandin and leukotriene synthesis, to its antibradykinin activity, as well as its lysosomal membrane-stabilizing action.<br\/>"},{"id":"319050-s-8","title":"Pharmacokinetics","sub":[{"id":"319050-s-8-23","title":"Absorption","mono":"<ul><li>Oral, capsule: time to peak concentration, 1.2 h +\/- 0.6 h<\/li><li>Oral, extended release capsule: time to peak concentration, 6.8 h +\/- 2.1 h<\/li><li>Bioavailability: approximately 90%<\/li><li>Effects of food, capsule (single-dose): Tmax increased from 1.89 to 4.76 hours; Cmax reduced by 39%<\/li><li>Effects of food, extended release capsule: High fat meal delays Tmax by about 2 h<\/li><\/ul>"},{"id":"319050-s-8-24","title":"Distribution","mono":"<ul><li>Vd: (IV), 0.1 L\/kg<\/li><li>Protein binding: greater than 99%<\/li><\/ul>"},{"id":"319050-s-8-25","title":"Metabolism","mono":"<ul><li>Glucuronide conjugation<\/li><li>Metabolite: acyl-glucuronide<\/li><\/ul>"},{"id":"319050-s-8-26","title":"Excretion","mono":"<ul><li>Renal: approximately 80% primarily as metabolites<\/li><li>Dialyzable: no (hemodialysis)<\/li><\/ul>"},{"id":"319050-s-8-27","title":"Elimination Half Life","mono":"<ul><li>(Capsule), 2.1 h +\/- 1.2 h<\/li><li>(Extended release capsule), 5.4 h +\/- 2.2 h<\/li><li>(IV), 2.05 h +\/- 0.58 h<\/li><li>Geriatrics: (capsule), prolonged by 26%<\/li><li>Geriatrics: (extended release capsule), prolonged by 54%<\/li><li>Patients with mild renal impairment: prolonged to approximately 3 h<\/li><li>Patients with moderate and severe renal impairment: prolonged to approximately 5 h to 9 h<\/li><\/ul>"}]},{"id":"319050-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/>May take with food, milk, or antacids to minimize gastrointestinal adverse effects <br\/>"},{"id":"319050-s-10","title":"Monitoring","mono":"<ul><li>dysmenorrhea\/pain: relief of pain<\/li><li>rheumatoid arthritis\/osteoarthritis: improved range of motion, decreased early morning stiffness and painful\/swollen joints, C-reactive protein levels, erythrocyte sedimentation rate<\/li><li>CBC, chemistry profile, blood pressure, fecal occult blood test, liver function; after initiation of NSAID therapy and every 6-12 months thereafter, more frequently in patients at risk for hepatic, renal, cardiac, or gastrointestinal toxicity (eg, age greater than 60 years, high-dose NSAID therapy, concurrent corticosteroids or anticoagulants, history of cardiac, renal, or hepatic disease)<\/li><li>hemoglobin, hematocrit; in patients with signs\/symptoms of anemia<\/li><li>signs and symptoms of skin reaction<\/li><\/ul>"},{"id":"319050-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Oral Capsule: 50 MG, 75 MG<\/li><li>Oral Capsule, Extended Release: 200 MG<\/li><\/ul><\/li><li><b>Orudis KT<\/b><br\/>Oral Tablet: 12.5 MG<br\/><\/li><li><b>Orudis<\/b><br\/>Oral Capsule: 75 MG<br\/><\/li><li><b>Oruvail<\/b><br\/>Oral Capsule, Extended Release: 150 MG, 200 MG<br\/><\/li><\/ul>"},{"id":"319050-s-12","title":"Toxicology","sub":[{"id":"319050-s-12-31","title":"Clinical Effects","mono":"<b>KETOPROFEN AND RELATED AGENTS <\/b><br\/>USES: Ketoprofen is used to treat patients with fever, pain, osteoarthritis, primary dysmenorrhea, and rheumatoid arthritis. PHARMACOLOGY: Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) with both analgesic and antipyretic activities. The exact mechanism of action is unknown but its anti-inflammatory effect is thought to be related to its ability to inhibit prostaglandin and leukotriene synthesis, to its antibradykinin activity, as well as its lysosomal membrane-stabilizing action. TOXICOLOGY: NSAIDs cause gastrointestinal irritation directly, and by inhibiting cyclooxygenase 1 (COX-1), which is necessary for the formation of the prostaglandins PG12 and PGE2; decrease in these prostaglandins results in decreased tissue mucus and bicarbonate secretion, increased hydrochloride secretion, and decreased gastric blood flow. The acidosis associated with severe NSAID overdose appears to result from the formation acidic metabolites, and mild hypotension. Prostaglandin inhibition by NSAIDs also causes renal arteriolar constriction, reduced renal blood flow and subsequent renal insufficiency in patients with conditions characterized by high angiotensin and low intravascular volume (eg, congestive heart failure, cirrhosis, hypovolemia). COX-1 inhibition also decreases the formation of thromboxane A2 which is necessary for platelet aggregation, predisposing patients to bleeding. EPIDEMIOLOGY: Overdose is rare. MILD TO MODERATE OVERDOSE: Reported effects of acute ketoprofen overdose are usually mild and include CNS depression (lethargy, drowsiness) or stimulation and gastrointestinal irritation (nausea, vomiting and epigastric pain). Symptoms develop soon after ingestion and usually resolve within 24 hours. SEVERE OVERDOSE: Rare effects include gastrointestinal bleeding, hypertension, acute renal failure, metabolic acidosis, tachycardia, psychosis; seizures have occurred following mixed ingestion overdose. ADVERSE EFFECTS: COMMON: Dyspepsia (11%). OTHER EFFECTS (3% TO 9%): Nausea, abdominal pain, diarrhea, constipation, flatulence, headache, dizziness, CNS inhibition (ie, depression, malaise, somnolence) or excitation (ie, insomnia, nervousness), and impaired renal function (ie, edema, increased BUN). RARE: Anorexia, vomiting, stomatitis, tinnitus, visual disturbance, rash, gastrointestinal bleeding, elevated liver enzymes, hypertension, palpitations, tachycardia, congestive heart failure, peripheral vascular disease, hemoptysis, dyspnea, bronchospasm, laryngeal edema, pruritus, skin eruptions, ecchymoses, sweating, purpura photosensitivity reactions, alopecia, and anaphylactoid reactions. CHRONIC: Renal impairment, hematuria, interstitial nephritis, nephrotic syndrome, and renal failure. <br\/>"},{"id":"319050-s-12-32","title":"Treatment","mono":"<b>KETOPROFEN AND RELATED AGENTS <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Treatment is symptomatic and supportive. Correct any significant fluid and\/or electrolyte abnormalities in patients with severe diarrhea and\/or vomiting. MANAGEMENT OF SEVERE TOXICITY: Treatment is symptomatic and supportive. Treat seizures with IV benzodiazepines; barbiturates or propofol may be needed if seizures persist or recur.<\/li><li>Decontamination: PREHOSPITAL: Prehospital gastrointestinal decontamination is not recommended because of the potential for CNS depression and subsequent aspiration. HOSPITAL: Administer activated charcoal to patients with recent and significant overdose who are alert and can protect the airway.<\/li><li>Airway management: Ensure adequate ventilation and perform endotracheal intubation early in patients with CNS depression or recurrent seizures (rare).<\/li><li>Antidote: None.<\/li><li>Gastrointestinal hemorrhage: Monitor stool guaiac, may give antacids, sucralfate.<\/li><li>Hypersensitivity reaction: MILD\/MODERATE: Antihistamines with or without inhaled beta agonists, corticosteroids or epinephrine. SEVERE: Oxygen, aggressive airway management, antihistamines, epinephrine, corticosteroids, ECG monitoring, and IV fluids.<\/li><li>Acidosis: Administer sodium bicarbonate 1 to 2 mEq\/kg intravenously for severe acidosis (pH less than 7.1). Monitor arterial pH and blood gases to guide bicarbonate therapy.<\/li><li>Monitoring of patient: Plasma concentrations are not readily available or clinically useful in the management of overdose. Monitor serum electrolytes in patients with significant vomiting and\/or diarrhea.  Monitor vital signs and mental status. Monitor liver enzymes and renal function following significant overdose. Monitor patients for gastrointestinal bleeding. If significant CNS or respiratory toxicity is present, assess acid-base status.<\/li><li>Enhanced elimination procedure: Hemodialysis is UNLIKELY to be of value because of the high degree of protein binding.<\/li><li>Patient disposition: HOME CRITERIA: A patient with an inadvertent exposure, that remains asymptomatic can be managed at home. OBSERVATION CRITERIA: Patients with a deliberate overdose, and those who are symptomatic, need to be monitored for several hours. Patients that remain asymptomatic can be discharged. ADMISSION CRITERIA: Patients who develop CNS depression, acidosis, or gastrointestinal bleeding should be admitted. CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in managing patients with severe toxicity or in whom the diagnosis is not clear.<\/li><\/ul>"},{"id":"319050-s-12-33","title":"Range of Toxicity","mono":"<b>KETOPROFEN AND RELATED AGENTS <\/b><br\/>TOXICITY: ADULTS: An elderly ingested 5 g of ketoprofen and did not develop any symptoms. A woman ingested 2.4 g of extended-release ketoprofen and ethanol and developed only epigastric pain. THERAPEUTIC DOSES: KETOPROFEN: ADULTS: Varies by indication; 75 mg 3 times per day or 50 mg 4 times per day; max, 300 mg\/day. Extended-release capsules: 200 mg once daily; max, 200 mg\/day CHILDREN: Varies by indication; the manufacturer reports that safety and efficacy of ketoprofen capsules and extended-release capsules have not been established in patients less than 18 years of age. However, studies have administered ketoprofen 25 to 50 mg twice daily to children for the treatment of juvenile chronic arthritis and doses of 0.5 to 1 mg\/kg to reduce fever in patients 3 months to 14 years of age. <br\/>"}]},{"id":"319050-s-13","title":"Clinical Teaching","mono":"<ul><li> This drug may cause edema, abdominal pain, constipation, diarrhea, dyspepsia, flatulence, nausea, dizziness, headache, insomnia, or tinnitus.<\/li><li>Patients with a history of cardiac disease or on a long-term treatment regimen are at an increased risk for adverse cardiovascular thrombotic events.  Advise patient to report signs\/symptoms of myocardial infarction or stroke.<\/li><li>Instruct patients to report signs\/symptoms of serious gastrointestinal events such as bleeding, ulceration, or perforation of stomach or intestines. Elderly and debilitated patients may be at an increased risk for this adverse effect.<\/li><li>Patient may take with food, milk, or antacids to minimize gastrointestinal irritation.<\/li><li>Advise patient to avoid use of additional NSAIDs without healthcare professional approval. <\/li><li> Patient should not drink alcohol while taking this drug.<\/li><\/ul>"}]}